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Background
Immunization with heterologous Env protein immuno-
gens following an immunologic rest period has the
potential to generate cross-clade neutralizing antibody
responses. We identified individuals who had received a
clade B Env protein with MF59 4-17 years earlier, most
in combination with a DNA or ALVAC prime, and
administered a clade C protein boost in an open label
phase 1 trial.
Methods
Sixteen previously primed volunteers and 20 naïve
volunteers each received 2 doses of a clade C TV1 tri-
meric Env protein with MF59 given 6 months apart.
HIV-1 specific CD4+ and CD8+ T cell responses were
measured by an intracellular cytokine staining (ICS)
assay. Antibody responses were measured with a Lumi-
nex binding antibody assay and a neutralizing antibody
assay in TZM-bl Cells.
Results
Despite the long interval, 31% of primed participants
demonstrated CD4+ T cell responses to Env at baseline,
which increased to 75% after a single protein boost. IgG
and IgA responses to TV1 trimeric Env were present in
64% (IgG) and 7% (IgA) of primed participants at base-
line, and rose to 93% and 85%, respectively, after one
dose of protein. 71% of primed participants demon-
strated neutralizing antibodies against Tier 1 clade B
isolate MN at baseline. After a single booster dose of
protein, 100% of the primed participants neutralized
MN and 93% showed neutralizing activity against a
clade C isolate, MW965.26. Unprimed participants did
not demonstrate CD4+ responses or antibody responses
to Env until after the second dose, which elicited IgG
and IgA responses to TV1 trimeric Env in 88% and
50%, respectively. Neutralizing antibody developed to
MN in 38% and to MW965.26 in 88% of the unprimed
participants.
Conclusion
These results demonstrate the durability of vaccine-eli-
cited HIV-1 specific antibody responses and support
current efforts to enhance the breadth and magnitude of
neutralizing antibodies through heterologous protein
prime-boost regimens.
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